Moxifloxacin versus levofloxacin for treatment of acute rhinosinusitis: A retrospective database analysis of treatment duration, outcomes, and charges

Current Medical Research and Opinion

Volumn 22, Issue 2, 2006, Pages 327-333

  Keating, Karen N ^a   Friedman, Howard S ^b   Perfetto, Eleanor M ^c  

^a BAYER CORPORATION   (United States)

^b Friedman Analytic Solutions Inc   (United States)

^c Weinberg Group Inc   (United States)

Author keywords

Acute rhinosinusitis; Antibiotic therapy; Fluoroquinolones; Recurrence; Therapy duration; Treatment charges; Treatment failure

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; OFLOXACIN; QUINOLINE DERIVATIVE;

ACUTE DISEASE; ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; RECURRENT INFECTION; RHINOSINUSITIS; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; ECONOMICS; MIDDLE AGED; RETROSPECTIVE STUDY; SINUSITIS; UNITED STATES;

ACUTE DISEASE; ADULT; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; DATABASE MANAGEMENT SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; OFLOXACIN; QUINOLINES; RETROSPECTIVE STUDIES; SINUSITIS; TREATMENT OUTCOME; UNITED STATES;

EID: 33645751070     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X80620     Document Type: Article

References (15)

1. Meltzer EO, Szwarcberg J, Pill MW. Allergic rhinitis, asthma, and rhinosinusitis: diseases of the integrated airway. J Manag Care Pharm 2004;10:310-7
2. Gooch 3rd WM. Antibacterial management of acute and chronic sinusitis. Manag Care Interface 1999;12:92-4
3. Ray NF, Baraniuk JN, Thamer M, et al. Healthcare expenditures for sinusitis in 1996: contributions of asthma, rhinitis, and other airway disorders. J Allergy Clin Immunol 1999;103:408-14
4. Piccirillo JF. Acute rhinosinusitis: staging, diagnosis/outcomes assessment. Infect Med 1998;15:16-25
5. Benninger MS, Sedory Holzer SE, Lau J. Diagnosis and treatment of uncomplicated acute bacterial rhinosinusitis: summary of the Agency for Health Care Policy and Research evidence-based report. Otolaryngol Head Neck Surg 2000;122:1-7
6. Anon JB, Jacobs MR, Poole MD, et al. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2004;130(Suppl 1):1-45
7. Scheid DC, Hamm RM. Acute bacterial rhinosinusitis in adults: part I. Evaluation. Am Fam Phys 2004;70:1685-92
8. Ferguson BJ. Acute and chronic sinusitis: how to ease symptoms and locate the cause. Postgrad Med 1995;97:45-57
9. Shalit I, Horev-Azaria L, Fabian I, et al. Immunomodulatory and protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide. Antimicrob Agents Chemother 2002;46:2442-9
10. Weiss T, Shalit I, Blau H, et al. Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother 2004;48:1974-82
11. Arnold SR, Straus SE. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database of Systematic Reviews, available from www.de.cochrane.org/review/en/ab003539.html [last accessed 15 November 2005]
12. Guillemot D, Carbon C, Vauzelle-Kervroëdan F, et al. Inappropriateness and variability of antibiotic prescribing among French office-based physicians. J Clin Epidemiol 1998;51:61-8
13. PharMetrics Overview. Available from http://www.pharmetrics. com/h_overview.html [last accessed 14 November 2005]
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:73-83
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-9